Skip to main content
. Author manuscript; available in PMC: 2017 Jun 8.
Published in final edited form as: Cell Host Microbe. 2016 May 26;19(6):865–873. doi: 10.1016/j.chom.2016.05.003

Figure 2. Antifungal treatment exacerbates allergic airway disease.

Figure 2

(A) Experimental setup for antifungal treatment and induction of allergic airway disease. Lung histology (H&E) (B), BAL cell counts (C), and serum antibody titers (D) from mice treated with (filled black bars) and without (open bars) fluconazole and immunized with HDM or not (PBS). (E) Representative intracellular cytokine staining (left panel) and quantification of cytokine producing CD4+ T cells (right panel) from HDM re-stimulated mediastinal lymph nodes from control and fluconazole treated mice. (F-H) Allergic airway disease in amphotericin-B-treated mice. H&E lung histology (F), representative FACS gating strategy showing eosinophil frequency (left panel) and quantification of total eosinophils (right panel) in the BAL (G), and serum antibody titers (H) in control (open bars) and amphotericin-treated (filled black bars) mice immunized with HDM. Data are representative of 4 (A-E) and 2 (F-H) independent experiments. Each dot represents an individual mouse. *P<0.05, **P<0.01 Student’s t-test. See also Figure S1.